-- 阿聯酋將於週五退出石油輸出國組織(歐佩克)。 Rystad Energy公司表示,此舉將削弱該組織的結構性力量。 阿聯酋已加入歐佩克超過五十年。 根據阿聯酋通訊社報道,阿聯酋此舉增強了其「應對市場動態的靈活性,同時繼續以審慎負責的方式為市場穩定做出貢獻」。阿聯酋能源和基礎設施部長蘇海爾·馬茲魯伊也在社群媒體平台X上分享了這篇文章。 受美國和以色列與伊朗戰爭的影響,石油市場面臨廣泛的供應中斷。在美伊停火以及以色列和黎巴嫩隨後達成停火協議後,衝突暫時停止。 阿聯酋通訊社的文章指出,“這一決定體現了阿聯酋的長期戰略和經濟願景以及不斷發展的能源結構,包括加快對國內能源生產的投資。” Rystad Energy在報告中指出,阿聯酋是歐佩克成員國中少數擁有剩餘產能的國家之一,沙烏地阿拉伯也名列其中。歐佩克採用產量配額制度來穩定全球石油市場。 Rystad地緣政治分析主管豪爾赫·萊昂寫道:“因此,阿聯酋的退出削弱了歐佩克管理市場能力的核心支柱之一。” 萊昂表示,隨著阿聯酋的退出,沙烏地阿拉伯將不得不承擔更多穩定油價的重任。 萊昂指出:「鑑於霍爾木茲海峽持續動盪以及更廣泛的地緣政治不確定性,短期影響可能較為有限,但長期影響更為深遠。一個結構性削弱的歐佩克,其內部剩餘產能減少,將越來越難以調節供應和穩定油價。」布蘭特原油上漲2.4%,至每桶110.82美元;西美元中質原油上漲2.4%,至每桶110.82美元;西美元。
Related Articles
Sector Update: Tech Stocks Fall Late Afternoon
Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.
Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data
Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%